These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 35718983)

  • 1. Investigating the ibrutinib resistance mechanism of L528W mutation on Bruton's tyrosine kinase via molecular dynamics simulations.
    Xu B; Liang L; Jiang Y; Zhao Z
    J Mol Graph Model; 2024 Jan; 126():108623. PubMed ID: 37716293
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Virtual screening and structure-activity relationship study of novel BTK inhibitors in Traditional Chinese Medicine for the treatment of rheumatoid arthritis.
    Sun L; Wang Z; Yang Z; Liu X; Dong H
    J Biomol Struct Dyn; 2023; 41(24):15219-15233. PubMed ID: 36914235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Revealing the Role of the Arg and Lys in Shifting Paradigm from BTK Selective Inhibition to the BTK/HCK Dual Inhibition - Delving into the Inhibitory Activity of KIN-8194 against BTK, and HCK in the Treatment of Mutated
    Elamin G; Aljoundi A; Alahmdi MI; Abo-Dya NE; Soliman MES
    Anticancer Agents Med Chem; 2024; 24(11):813-825. PubMed ID: 36752293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular Insights into the Impact of Mutations on the Binding Affinity of Targeted Covalent Inhibitors of BTK.
    Awoonor-Williams E; Abu-Saleh AAA
    J Phys Chem B; 2024 Mar; 128(12):2874-2884. PubMed ID: 38502552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent research of BTK inhibitors: Methods of structural design, pharmacological activities, manmade derivatives and structure-activity relationship.
    Wang L; Zhang Z; Yu D; Yang L; Li L; He Y; Shi J
    Bioorg Chem; 2023 Sep; 138():106577. PubMed ID: 37178649
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Computational Investigation of the Covalent Inhibition Mechanism of Bruton's Tyrosine Kinase by Ibrutinib.
    Barragan AM; Ghaby K; Pond MP; Roux B
    J Chem Inf Model; 2024 Apr; 64(8):3488-3502. PubMed ID: 38546820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Zanubrutinib in Mantle Cell Lymphoma Management: A Comprehensive Review.
    Alsuhebany N; Pan C; Holovac E; Do B; McBride A
    Blood Lymphat Cancer; 2023; 13():67-76. PubMed ID: 38034984
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bruton's Tyrosine Kinase Inhibitors for Multiple Sclerosis Treatment: A New Frontier.
    Greenberg BM
    Neurol Clin; 2024 Feb; 42(1):155-163. PubMed ID: 37980113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lysine-Reactive
    Kawano M; Murakawa S; Higashiguchi K; Matsuda K; Tamura T; Hamachi I
    J Am Chem Soc; 2023 Dec; 145(48):26202-26212. PubMed ID: 37987622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Computational Investigations on Reaction Mechanisms of the Covalent Inhibitors Ponatinib and Analogs Targeting the Extracellular Signal-Regulated Kinases.
    Tian Y; Zhang M; Heng P; Hou H; Wang B
    Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bruton's tyrosine kinase inhibitors in primary central nervous system lymphoma: New hopes on the horizon.
    Lino-Silva LS; Martínez-Villavicencio SB; Rivera-Moncada LF
    World J Clin Oncol; 2024 May; 15(5):587-590. PubMed ID: 38835851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elucidating the binding mechanisms of GABA and Muscimol as an avenue to discover novel GABA-mimetic small molecules.
    Issahaku AR; Wilhelm A; Schutte-Smith M; Erasmus E; Visser H
    J Biomol Struct Dyn; 2024 Mar; ():1-16. PubMed ID: 38520326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microscopic Modes and Free Energies for Topoisomerase I-DNA Covalent Complex Binding with Non-campothecin Inhibitors by Molecular Docking and Dynamics Simulations.
    Wei NN; Hamza A; Hao C; Xiu Z; Zhan CG
    Theor Chem Acc; 2013 Aug; 132(8):. PubMed ID: 24363608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigating the Impact of Covalent and Non-covalent Binding Modes of Inhibitors on Bruton's Tyrosine Kinase in the Treatment of B Cell Malignancies - Computational Insights.
    Issahaku AR; Soliman MES
    Curr Pharm Biotechnol; 2023; 24(6):814-824. PubMed ID: 35718983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of Intermolecular Interactions of Irreversible and Reversible Inhibitors with Bruton's Tyrosine Kinase via Molecular Dynamics Simulations.
    Yu X; Qiu S; Sun D; Guo P; Li Q
    Molecules; 2022 Nov; 27(21):. PubMed ID: 36364276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of Bruton's tyrosine kinase in B cells and malignancies.
    Pal Singh S; Dammeijer F; Hendriks RW
    Mol Cancer; 2018 Feb; 17(1):57. PubMed ID: 29455639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A non-covalent inhibitor XMU-MP-3 overrides ibrutinib-resistant Btk
    Gui F; Jiang J; He Z; Li L; Li Y; Deng Z; Lu Y; Wu X; Chen G; Su J; Song S; Zhang YM; Yun CH; Huang X; Weisberg E; Zhang J; Deng X
    Br J Pharmacol; 2019 Dec; 176(23):4491-4509. PubMed ID: 31364164
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
    Guo Y; Liu Y; Hu N; Yu D; Zhou C; Shi G; Zhang B; Wei M; Liu J; Luo L; Tang Z; Song H; Guo Y; Liu X; Su D; Zhang S; Song X; Zhou X; Hong Y; Chen S; Cheng Z; Young S; Wei Q; Wang H; Wang Q; Lv L; Wang F; Xu H; Sun H; Xing H; Li N; Zhang W; Wang Z; Liu G; Sun Z; Zhou D; Li W; Liu L; Wang L; Wang Z
    J Med Chem; 2019 Sep; 62(17):7923-7940. PubMed ID: 31381333
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.